Ahad Lodhi, MD
Nephrology · Lake Charles, LANPI 1982833851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 286 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$864
- Otsuka America Pharmaceutical, Inc.$633
- Mallinckrodt Hospital Products Inc.$610
- ANI Pharmaceuticals, Inc.$596
- Akebia Therapeutics Inc$584
- Amgen$482
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,73493%
- Education$4507%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $864 |
| Otsuka America Pharmaceutical, Inc. | 30 | $633 |
| Mallinckrodt Hospital Products Inc. | 23 | $610 |
| ANI Pharmaceuticals, Inc. | 26 | $596 |
| Akebia Therapeutics Inc | 32 | $584 |
| Amgen(2 entities) | 19 | $482 |
| Vifor Pharma, Inc. | 23 | $471 |
| Bayer | 13 | $281 |
| Calliditas Therapeutics US Inc. | 9 | $231 |
| Fresenius USA Marketing, Inc. | 10 | $192 |
| Nxstage Medical, Inc. | 2 | $177 |
| Daiichi Sankyo Inc. | 9 | $149 |
| Novartis | 6 | $124 |
| GSK | 7 | $122 |
| Aurinia Pharma U.S., Inc. | 6 | $111 |
| Travere Therapeutics, Inc. | 5 | $107 |
| Kyowa Kirin, Inc. | 4 | $81 |
| Boehringer Ingelheim | 4 | $78 |
| Pharmacosmos Therapeutics Inc. | 3 | $68 |
| Mallinckrodt Enterprises LLC | 4 | $60 |
| Ardelyx, Inc. | 2 | $55 |
| Novo Nordisk | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
How this compares
$6,184 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 218 | $144,080 |
| JardianceEmpagliflozin | 65 | $55,154 |
| VelphoroSucroferric Oxyhydroxide | 14 | $48,811 |
| VeltassaPatiromer Calcium Sorbitex | 40 | $48,457 |
| AuryxiaFerric Citrate | 14 | $22,917 |
| KerendiaFinerenone | 16 | $18,976 |
| EntrestoSacubitril/Valsartan | 23 | $14,698 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $11,079 |
| Lanthanum Carbonate | 11 | $10,000 |
| Sevelamer Carbonate | 86 | $9,008 |
| Cinacalcet Hcl | 15 | $7,159 |
| Calcium Acetate | 77 | $4,871 |
| Losartan Potassium | 300 | $2,327 |
| Clonidine | 33 | $2,160 |
| Nifedipine ErNifedipine | 141 | $2,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $864 | $155,159232 claims |
| Boehringer IngelheimJardiance | $78 | $55,15465 claims |
| Fresenius USA Marketing, Inc.Velphoro | $192 | $48,81114 claims |
| Akebia Therapeutics IncAuryxia | $584 | $22,91714 claims |
| BayerKerendia | $281 | $18,97616 claims |
| NovartisEntresto | $124 | $14,69823 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $596 | $62823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Lake Charles
- Abdel Abu ShamatLake Charles$6K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Jon MaresCovington$103K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
- Michael LiuOpelousas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.